TY  - JOUR

T1  - Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - Pharmacoeconomics

UR  - http://eprints.whiterose.ac.uk/121723/

PY  - 2017/09/20

AU  - Bermejo I

AU  - Stevenson M

AU  - Cooper K

AU  - Harnan S

AU  - Hamilton J

AU  - Clowes M

AU  - Carroll C

AU  - Harrison T

AU  - Saha S

ED  - 

DO  - DOI: 10.1007/s40273-017-0571-8

Y2  - 2024/12/21

ER  -